Reasons To Limit Inventor Testimony In Hatch-Waxman Cases

By Michael Hogan (February 14, 2019, 2:59 PM EST) -- Inventor testimony inevitably forms a part of every generic drug company's case in a Paragraph IV obviousness challenge under the Hatch-Waxman Act.[1] This is odd because the generic defendant in its validity challenge cannot use anything that the inventors did in support of its obviousness case; but, ironically, the patentee/innovator company can.[2] Given the success rate of Paragraph IV obviousness challenges and the legal framework for the obviousness analysis, one can only wonder why this costly practice continues....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!